Screener
Immunovant, Inc. IMVT Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Cash flows from operating activities | |||
| Net loss | $(505,606) | $(413,840) | $(259,336) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation | 55,724 | 49,487 | 41,116 |
| Depreciation on property and equipment | 409 | 377 | 231 |
| Non-cash lease expense | 99 | 133 | 1,130 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | 986 | 3,232 | (4,577) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s stock-based comp?
- Immunovant, Inc. (IMVT) reported stock-based comp of $11.14M in Q1 2026.
- How has Immunovant, Inc.'s stock-based comp changed year-over-year?
- Immunovant, Inc.'s stock-based comp decreased by 4.7% year-over-year, from $11.69M to $11.14M.
- What is the long-term trend for Immunovant, Inc.'s stock-based comp?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s stock-based comp has grown at a 12.9% compound annual growth rate (CAGR), from $34.24M to $55.72M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Immunovant, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude